Key Insights on Gross Profit: Alnylam Pharmaceuticals, Inc. vs Exelixis, Inc.

Biotech Giants: Alnylam vs. Exelixis Profit Battle

__timestampAlnylam Pharmaceuticals, Inc.Exelixis, Inc.
Wednesday, January 1, 20145056100023068000
Thursday, January 1, 20154109700033277000
Friday, January 1, 201647159000184902000
Sunday, January 1, 201776545000437411000
Monday, January 1, 201873106000827478000
Tuesday, January 1, 2019194688000934678000
Wednesday, January 1, 2020414801000951266000
Friday, January 1, 20217041430001382097000
Saturday, January 1, 20228686010001553153000
Sunday, January 1, 202315178860001757661000
Monday, January 1, 202419248730002168701000
Loading chart...

In pursuit of knowledge

A Tale of Two Biotechs: Alnylam vs. Exelixis

In the dynamic world of biotechnology, Alnylam Pharmaceuticals and Exelixis, Inc. have emerged as key players, each carving out a unique path to profitability. Over the past decade, Exelixis has consistently outperformed Alnylam in terms of gross profit, with a staggering 6600% increase from 2014 to 2023. Alnylam, while trailing, has shown impressive growth, achieving a 2900% rise in the same period.

Key Insights

  • Exelixis' Dominance: By 2023, Exelixis' gross profit reached nearly 1.76 billion, a testament to its robust product pipeline and strategic market positioning.
  • Alnylam's Growth: Despite starting with a modest 50 million in 2014, Alnylam's gross profit surged to 1.52 billion by 2023, reflecting its innovative RNAi therapeutics.

This comparison highlights the diverse strategies and market dynamics shaping the biotech industry today.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025